This study is no longer recruiting participants.
The University of Washington is seeking volunteers for a Phase 1/2 COVID-19 vaccine booster trial. The purpose of this clinical trial is to test the safety and effectiveness of a booster dose of the Novavax sub-unit protein vaccine in people who have received an EUA vaccine series.
The study will enroll:
- Participants who have completed an EUA vaccine series at least 12 weeks prior to joining the study.
- This includes individuals who have received either 2 doses of Pfizer OR 2 doses of Moderna OR 2 doses of Johnson & Johnson COVID-19 vaccines. You will not be eligible if you have received a 3rd (booster) COVID-19 vaccine.
The trial will last for about one year and will involve at least 7 in-person visits.
Participants will undergo a screening assessment to see whether they are eligible. Study visits will involve physical exams, blood draws, and vaccine injections. Participants will be asked to keep a diary of their vaccine reactions for 7 days after each injection.
To be eligible for the trial you must:
- Be 18 years of age or older
- Have received an EUA vaccine no less than 12 weeks ago
Conditions which would prevent you from participating:
- Previous SARS-CoV-2 infection
- Current pregnancy or breastfeeding
- Serious reactions to vaccines
- Immunocompromising conditions
Compensation:
For completing the entire study, participants will be compensated $800.
Clinic Location: Our clinic is located on the 11th floor of the Ninth and Jefferson Building at Harborview Medical Center. We are open Monday through Friday 8:00am to 5:00pm.
Please contact us at 206-520-4212 or email us at vteu@uw.edu for more information. You can also find more information on the NIH’s webpage for this clinical trial.